PRESS RELEASE

New York, NY (February 4, 2013) – Retrophin (OTCQB: RTRX), a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced that Martin Shkreli, Founder & Chief Executive Officer, will be presenting at the 15^th Annual BIO CEO & Investor Conference, which is being held February 11-12 in New York, NY. Shkreli will provide corporate updates and discuss upcoming clinical milestones, including enrollment in a potentially pivotal Phase II clinical trial of Retrophin’s lead compound, RE-021.

Details of the presentation are as follows:

Date: Tuesday, February 12
Time: 3:30 p.m. ET
Location: The Waldorf Astoria New York

A webcast of the presentation will be available on Retrophin’s web site: http://www.retrophin.com/.

About Retrophin

Retrophin is a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for focal segmental glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. The company’s lead compound, RE-021, formerly known as DARA, is scheduled to begin enrollment in a potentially pivotal Phase II clinical trial for FSGS in the first half of 2013.

Retrophin Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Retrophin’s business. Retrophin undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

# # #

Contacts: